Yu-Lin Chung-Nielsen
Internal Medicine · Dallas, TXNPI 1497913933
Payments from drug & device makers
Across 178 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$280
- SK Life Science, Inc.$278
- Neurocrine Biosciences, Inc.$258
- Amarin Pharma, Inc.$215
- AbbVie$204
- Pfizer$181
- plus $2K from 36 others
What the payments were for
- Food & beverage$3,226100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,232 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 40 | $54,326 |
| JardianceEmpagliflozin | 22 | $34,277 |
| EliquisApixaban | 13 | $18,596 |
| RybelsusSemaglutide | 12 | $11,243 |
| Atorvastatin Calcium | 132 | $3,704 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 11 | $3,309 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 15 | $3,114 |
| Ezetimibe | 25 | $2,624 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 14 | $1,830 |
| Rosuvastatin Calcium | 51 | $1,823 |
| Tamsulosin Hcl | 25 | $1,434 |
| Losartan Potassium | 78 | $1,419 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 19 | $1,240 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 14 | $1,133 |
| Amlodipine Besylate | 109 | $1,073 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $86 | $65,56952 claims |
| Boehringer IngelheimJardiance | $15 | $34,27722 claims |
| PfizerEliquis, Abrysvo | $181 | $21,90524 claims |
| GSKShingrix | $79 | $3,11415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Dallas
- Amit VermaDallas$7.7M
- Valentine EbuhDallas$6.8M
- Gary SinclairDallas$3.4M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.